Stability study of cefepime in different infusion solutions

被引:29
作者
RabouanGuyon, SM
Guet, AF
Courtois, PY
Barthes, DMC
机构
[1] UNIV POITIERS,CHIM ANALYT LAB,FAC MED & PHARM,F-86005 POITIERS,FRANCE
[2] UNIV POITIERS,INST XENOBIOT,FAC MED & PHARM,F-86005 POITIERS,FRANCE
关键词
stability; cefepime; polyethylene; infusion;
D O I
10.1016/S0378-5173(97)00137-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The stability of cefepime in the formulation Axepim(R) diluted with 0.9% sodium chloride or with 5% glucose in a three layer laminate bag Clear-Flex(R) (polyethylene container) was investigated at 24 +/- 2 degrees C in daylight and at 4 +/- 2 degrees C in the dark (initial concentration was 8 mg ml(-1)). Stability was defined as at least 90% of the initial concentration. Analyses were performed by reversed phase high performance liquid chromatography, with a method previously validated. This was specific, linear (r greater than or equal to 0.9995), sensitive (CV < 0.44%) and reproducible (CV < 1.26%). The limit of detection was 0.1 mu g ml(-1) and limit of quantification was 1 mu g ml(-1). This study showed the changes in the stability of cefepime over 48 h at 24 +/- 2 degrees C in daylight, or 15 days at 4 +/- 2 degrees C in the dark. The yellowish coloration which appeared in some solutions, indicated visually a degradation of cefepime. IR and NMR spectra showed that this coloration was linked to the destruction of the Delta-cephem ring of the molecule. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:185 / 190
页数:6
相关论文
共 12 条
[1]  
[Anonymous], STP PHARM PRATIQUES
[2]   STABILITY AND COMPATIBILITY OF ETOPOSIDE IN 0.9-PERCENT SODIUM-CHLORIDE INJECTION IN 3 CONTAINERS [J].
BARTHES, DMC ;
ROCHARD, EB ;
POULIQUEN, IJ ;
RABOUAN, SM ;
COURTOIS, PY .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1994, 51 (21) :2706-2709
[3]  
DOWNIE G, 1985, BR J PARENT THER, V11, P142
[4]   MIGRATION OF A PHTHALATE ESTER PLASTICIZER FROM POLYVINYL-CHLORIDE BLOOD BAGS INTO STORED HUMAN BLOOD AND ITS LOCALIZATION IN HUMAN TISSUES [J].
JAEGER, RJ ;
RUBIN, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1972, 287 (22) :1114-&
[5]   ACTIVITY OF CEFEPIME (BMY-28142) AND CEFPIROME (HR 810) AGAINST GRAM-NEGATIVE BACILLI RESISTANT TO CEFOTAXIME OR CEFTAZIDIME [J].
JONES, RN ;
FUCHS, PC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 23 (01) :163-165
[6]  
JOUKO K, 1982, AM J HOSP PHARM, V39, P1018
[7]  
JUNGTOMO J, 1991, ANTIMICROB AGENTS CH, V12, P2652
[8]   COMPARISON OF A NEW CEPHALOSPORIN, BMY 28142, WITH OTHER BROAD-SPECTRUM BETA-LACTAM ANTIBIOTICS [J].
KESSLER, RE ;
BIES, M ;
BUCK, RE ;
CHISHOLM, DR ;
PURSIANO, TA ;
TSAI, YH ;
MISIEK, M ;
PRICE, KE ;
LEITNER, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 27 (02) :207-216
[9]   ACTIVITY OF CEFEPIME, CEFTAZIDIME, AND CEFTIZOXIME AGAINST MUTANTS OF ENTEROBACTERIACEAE AND PSEUDOMONAS-AERUGINOSA DEREPRESSED FOR CLASS-I BETA-LACTAMASE [J].
KNAPP, CC ;
WASHINGTON, JA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 24 (06) :1011-1012
[10]   PHOTODEGRADATION PATHS OF CEFOTAXIME [J].
LERNER, DA ;
BONNEFOND, G ;
FABRE, H ;
MANDROU, B ;
DEBUOCHBERG, MS .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1988, 77 (08) :699-703